Anna Szafran-Swietlik, MD
Endocrinology, Diabetes & Metabolism · Hudson, FLNPI 1780815340
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.3% of the total across 737 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 50 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations.
Across 737 payments — averaging $21.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Medtronic$2K
- Amgen$1K
- Corcept Therapeutics$1K
- Lilly USA, LLC$1K
- Bayer$980
- plus $7K from 44 others
Across 26 payments — averaging $12,451 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$324K
What the payments were for
- Travel & lodging$1,2278%
- Food & beverage$14,45891%
- Education$1581%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 670G System$1,269
- MINIMED 780G$291
- Omnipod$139
- MYCAPSSA$125
- Korlym$101
- EVENITY$101
How this compares
$15,843 in reported general payments places this provider in the 80th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 639 | $1,013,274 |
| CrysvitaBurosumab-Twza | 21 | $422,012 |
| JardianceEmpagliflozin | 312 | $409,071 |
| MounjaroTirzepatide | 223 | $325,401 |
| Tresiba Flextouch U-100Insulin Degludec | 190 | $137,066 |
| Tresiba Flextouch U-200Insulin Degludec | 77 | $114,604 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 71 | $101,164 |
| RybelsusSemaglutide | 45 | $86,550 |
| TrulicityDulaglutide | 57 | $83,530 |
| JanuviaSitagliptin Phosphate | 63 | $83,374 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 64 | $77,864 |
| ForteoTeriparatide | 11 | $71,060 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 82 | $65,401 |
| Repatha SureclickEvolocumab | 60 | $63,647 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $63,513 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog, Tresiba | $2,455 | $1,160,388782 claims |
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $1,076 | $501,889356 claims |
| Boehringer IngelheimJardiance, Tradjenta | $520 | $426,372328 claims |
| Kyowa Kirin, Inc.Crysvita | $83 | $422,01221 claims |
| MerckJanuvia | $177 | $83,37463 claims |
| AmgenProlia | $1,422 | $51,27429 claims |
| AbbVieSynthroid | $138 | $11,518112 claims |
| AstraZenecaFarxiga | $375 | $11,04715 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $289 | $7,003632 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Hudson
- Ania JanickaHudson$475K
- Antonio Pinero PilonaHudson$69K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Richard PratleyOrlando$735K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.